Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

2.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

PMID:
24418728
3.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

4.

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.

Lung Cancer. 2014 May;84(2):121-6. doi: 10.1016/j.lungcan.2014.02.007. Epub 2014 Feb 19.

PMID:
24629636
5.

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.

Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M.

Clin Cancer Res. 2012 Dec 15;18(24):6599-608. doi: 10.1158/1078-0432.CCR-12-0838. Epub 2012 Oct 10.

6.

Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.

Yoon HJ, Sohn I, Cho JH, Lee HY, Kim JH, Choi YL, Kim H, Lee G, Lee KS, Kim J.

Medicine (Baltimore). 2015 Oct;94(41):e1753. doi: 10.1097/MD.0000000000001753.

7.

ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.

Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M.

Lung Cancer. 2016 Apr;94:22-7. doi: 10.1016/j.lungcan.2016.01.011. Epub 2016 Jan 21.

PMID:
26973202
8.

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.

Lindquist KE, Karlsson A, Levéen P, Brunnström H, Reuterswärd C, Holm K, Jönsson M, Annersten K, Rosengren F, Jirström K, Kosieradzki J, Ek L, Borg Å, Planck M, Jönsson G, Staaf J.

Oncotarget. 2017 May 23;8(21):34796-34810. doi: 10.18632/oncotarget.16276.

9.

[Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].

Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.

Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):639-43. Chinese.

PMID:
26705279
10.

Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.

Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.

Lab Invest. 2018 Mar;98(3):371-379. doi: 10.1038/labinvest.2017.124. Epub 2017 Dec 18.

11.

A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.

Wijesinghe P, Bepler G, Bollig-Fischer A.

J Thorac Oncol. 2015 Feb;10(2):381-6. doi: 10.1097/JTO.0000000000000337.

12.

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.

Rogers TM, Arnau GM, Ryland GL, Huang S, Lira ME, Emmanuel Y, Perez OD, Irwin D, Fellowes AP, Wong SQ, Fox SB.

Sci Rep. 2017 Feb 9;7:42259. doi: 10.1038/srep42259.

13.

Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.

Song Z, Yu X, Zhang Y.

Cancer Biol Ther. 2017 Nov 2;18(11):883-887. doi: 10.1080/15384047.2016.1235660. Epub 2016 Sep 16.

14.

RET, ROS1 and ALK fusions in lung cancer.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y.

Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.

PMID:
22327623
15.

Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CD, Alaggio R.

Am J Surg Pathol. 2015 Jul;39(7):957-67. doi: 10.1097/PAS.0000000000000404.

16.

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.

Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, Mao M, Han J, Kim J, Choi YL.

Mod Pathol. 2015 Apr;28(4):468-79. doi: 10.1038/modpathol.2014.107. Epub 2014 Sep 19.

17.

Emerging Biomarkers in Personalized Therapy of Lung Cancer.

Cagle PT, Raparia K, Portier BP.

Adv Exp Med Biol. 2016;890:25-36. doi: 10.1007/978-3-319-24932-2_2. Review.

PMID:
26703797
18.

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.

Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.

Pathol Res Pract. 2018 Apr;214(4):572-578. doi: 10.1016/j.prp.2018.02.001. Epub 2018 Feb 16.

19.

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Gainor JF, Shaw AT.

Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. Review.

20.

ROS1 fusions in Chinese patients with non-small-cell lung cancer.

Cai W, Li X, Su C, Fan L, Zheng L, Fei K, Zhou C, Manegold C, Schmid-Bindert G.

Ann Oncol. 2013 Jul;24(7):1822-7. doi: 10.1093/annonc/mdt071. Epub 2013 Mar 20.

PMID:
23514723

Supplemental Content

Support Center